YER187W Antibody

What is YER187W Antibody and what is its target in research applications?

YER187W Antibody is a polyclonal antibody developed against the YER187W protein (UniProt No. P40102) from Saccharomyces cerevisiae (Baker's yeast, strain ATCC 204508/S288c). This antibody is specifically raised in rabbits using recombinant Saccharomyces cerevisiae YER187W protein as the immunogen. It is produced through antigen affinity purification methods and is intended exclusively for research applications, not for diagnostic or therapeutic purposes .

The antibody exists in liquid form and is non-conjugated, formulated in a storage buffer containing 0.03% Proclin 300 as a preservative, 50% glycerol, and 0.01M PBS at pH 7.4. Being a polyclonal IgG antibody, it contains multiple antibody clones recognizing different epitopes of the YER187W protein .

What experimental applications has YER187W Antibody been validated for?

The YER187W Antibody has been specifically validated for two primary applications:

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of YER187W protein in solution-based assays

• Western Blotting (WB): For detection of YER187W protein in cell lysates and protein samples separated by gel electrophoresis

These validation tests are essential for establishing antibody specificity. When selecting antibodies for experimental applications, researchers should prioritize antibodies with documented knockout characterization data, as this significantly increases confidence in antibody specificity and performance .

What are the optimal storage conditions for maintaining YER187W Antibody activity?

To maintain optimal activity of YER187W Antibody, the following storage conditions are recommended:

Long-term stability is best achieved at -80°C, while working aliquots can be stored at -20°C. Research indicates that antibody functionality can be compromised by repeated freezing and thawing, which can lead to protein denaturation and aggregation, ultimately reducing binding efficacy .

How should researchers validate YER187W Antibody before incorporating it into their experimental workflow?

Comprehensive validation of YER187W Antibody should include the following steps:

Recent studies from YCharOS have highlighted that genetic control data (particularly knockout controls) is the most reliable predictor of antibody specificity. Their comprehensive analysis of 614 antibodies revealed that antibodies with genetic control data on manufacturer websites were more likely to perform satisfactorily .

What controls should be implemented when using YER187W Antibody in Western blotting experiments?

When performing Western blot experiments with YER187W Antibody, the following controls are essential:

• Genetic knockout control: Include lysates from YER187W-knockout yeast strains. A selective antibody will show bands only in the wild-type lane and not in the knockout lane .

• Loading control: Include detection of a housekeeping protein (e.g., actin or GAPDH) to ensure equal loading across samples.

• Primary antibody omission: Include a lane where primary antibody is omitted to identify non-specific binding from the secondary antibody.

• Blocking peptide competition: Pre-incubate the antibody with excess immunizing peptide to confirm signal specificity.

• Molecular weight verification: Confirm that detected bands align with the expected molecular weight of YER187W protein, considering potential post-translational modifications.

Recent analysis by YCharOS demonstrates that even when a Western blot shows high selectivity, this should not be used as evidence for selectivity in other applications such as immunofluorescence or immunoprecipitation, as performance across applications can vary significantly .

What methodological approaches can improve antibody performance in challenging experimental conditions?

To optimize YER187W Antibody performance in challenging experimental conditions:

• Buffer optimization: Adjust blocking agents (BSA vs. milk) and detergent concentrations to reduce background and enhance specific signal.

• Sample preparation modifications: Consider different lysis buffers or protein extraction methods that may better preserve the epitope structure.

• Signal enhancement strategies: Implement amplification systems or more sensitive detection methods for low-abundance targets.

• Membrane selection: For Western blotting, compare PVDF and nitrocellulose membranes to determine optimal protein binding and signal-to-noise ratio.

• Epitope retrieval: For fixed samples, test different antigen retrieval methods if the epitope may be masked.

Studies indicate that polyclonal antibodies like YER187W Antibody often exhibit variable performance across applications. A comprehensive analysis by YCharOS found that polyclonal antibodies frequently underperformed, contrary to the conventional assumption that binding to multiple epitopes confers higher efficiency .

How can computational models be integrated with YER187W Antibody experiments to enhance data interpretation?

Computational modeling approaches can significantly enhance YER187W Antibody experimental design and data interpretation:

• Binding mode prediction: Biophysics-informed models can identify distinct binding modes associated with specific ligands, potentially helping predict cross-reactivity of YER187W Antibody with related proteins. These models associate each potential ligand with a distinct binding mode, enabling prediction beyond experimentally observed interactions .

• Active learning strategies: Implement machine learning approaches to predict antibody-antigen binding and optimize experimental resource utilization. Active learning has been shown to reduce the number of experiments needed to reach accurate predictions of antibody-antigen binding .

• Specificity profile customization: Computational design methods can help engineer modified antibodies with customized specificity profiles, either with specific high affinity for a particular target or with cross-specificity for multiple targets .

• Experimental iteration optimization: Simulation-based evaluations can compare different machine learning strategies on synthetic datasets to determine which strategy will work best for actual experimental datasets before committing laboratory resources .

Machine learning models trained on antibody selection data can disentangle binding modes even between chemically similar ligands, offering a powerful approach to predict and generate specific antibody variants beyond those observed in initial experiments .

What considerations should researchers address when using YER187W Antibody in co-immunoprecipitation (Co-IP) studies?

When using YER187W Antibody for co-immunoprecipitation studies:

• Binding efficiency assessment: Evaluate the antibody's ability to recognize the native (non-denatured) form of YER187W protein. Not all antibodies that perform well in Western blotting will function efficiently in Co-IP studies.

• Crosslinking considerations: Determine whether chemical crosslinking is necessary to capture transient protein-protein interactions.

• Buffer optimization: Test different lysis and washing buffers to balance between preserving protein-protein interactions and reducing non-specific binding.

• Elution strategy selection: Compare different elution methods (competitive elution with immunizing peptide, pH shift, etc.) to identify the approach that yields the highest purity and recovery.

• Controls implementation:

  • Input control (pre-IP sample)

  • IgG control (non-specific rabbit IgG)

  • Knockout/knockdown control

  • Reciprocal IP (if antibodies to interaction partners are available)

Recent research indicates that polyclonal antibodies may underperform in immunoprecipitation experiments compared to expectations. The YCharOS study found that contrary to conventional assumptions, polyclonal antibodies did not consistently provide higher efficiency in immunoprecipitation despite binding to multiple epitopes .

How can recombinant antibody technology be applied to improve upon conventional YER187W Antibody limitations?

Recombinant antibody technologies offer several advantages that can address limitations of conventional YER187W polyclonal antibodies:

• Reproducibility enhancement: Unlike polyclonal antibodies that vary between lots, recombinant antibodies provide consistent performance across batches. The encoded sequence ensures reproducibility and eliminates batch-to-batch variation .

• Format flexibility: Recombinant antibodies can be engineered into various formats including full-length antibodies, Fab fragments, single-chain variable fragments (scFvs), and nanobodies, each optimized for specific applications .

• Intracellular expression: Recombinant antibodies can be expressed intracellularly (intrabodies) as genetically encoded tools to control protein function within living cells, offering temporal and spatial control over target inhibition .

• Specificity engineering: Computational approaches combined with experimental selection can design antibodies with customized specificity profiles beyond those observed in natural antibody repertoires .

• Affinity maturation: Directed evolution techniques can enhance binding affinity and specificity through iterative selection processes guided by computational models .

Renewable and recombinant antibodies have demonstrated significant value in controlling protein function in various applications, offering advantages in consistency, reproducibility, and customization potential compared to conventional polyclonal antibodies .

What quantitative approaches are recommended for analyzing Western blot data generated using YER187W Antibody?

For rigorous quantitative analysis of Western blot data using YER187W Antibody:

• Normalization strategy selection:

  • Housekeeping protein normalization (accounting for expression stability)

  • Total protein normalization using stain-free technology or Ponceau S

  • Normalization to multiple reference proteins for enhanced accuracy

• Densitometry guidelines:

  • Use linear range calibration curves to ensure measurements fall within the linear dynamic range

  • Apply background subtraction consistently across all samples

  • Analyze technical replicates to establish measurement variability

• Statistical analysis implementation:

  • For multiple comparisons: ANOVA with appropriate post-hoc tests

  • For time-course experiments: repeated measures analysis

  • Include propagation of error calculations when performing ratio-based normalization

• Data presentation standards:

  • Include representative blot images showing all experimental conditions

  • Present normalized quantitative data with appropriate error bars

  • Report sample size, statistical tests, and significance levels

When interpreting Western blot data, researchers should be aware that antibodies might detect multiple bands representing different forms of the protein (splice variants, post-translational modifications, multimers). A selective antibody may display multiple wild-type bands while showing no bands in the knockout sample .

What troubleshooting approaches are recommended when YER187W Antibody yields unexpected results?

When encountering unexpected results with YER187W Antibody, implement the following systematic troubleshooting approach:

How should researchers incorporate antibody validation data into their methodology sections when publishing research using YER187W Antibody?

When reporting research utilizing YER187W Antibody, methodology sections should include:

• Complete antibody identification:

  • Manufacturer and catalog number (CSB-PA340210XA01SVG)

  • Antibody Registry identifier (if available)

  • Clone designation for monoclonals or lot number for polyclonals

  • RRID (Research Resource Identifier) when applicable

• Validation documentation:

  • Description of validation procedures performed (e.g., knockout controls, specificity tests)

  • Citation of published validation studies if available

  • Deposition of validation data in public repositories when possible

• Application-specific details:

  • Working concentration/dilution used for each application

  • Incubation conditions (time, temperature, buffer composition)

  • Detection methods employed

  • Image acquisition parameters

• Control implementations:

  • Detailed description of positive and negative controls

  • Inclusion of representative control data in supplementary materials

According to current best practices, transparent reporting of antibody validation is crucial for experimental reproducibility. The YCharOS initiative emphasizes the importance of knockout characterization data in establishing antibody reliability and selectivity, with data being made publicly accessible through repositories such as Zenodo and indexed via PubMed .

How might emerging technologies enhance the utility of antibodies like YER187W in yeast proteome research?

Emerging technologies poised to enhance YER187W Antibody utility include:

• Single-cell antibody-based proteomics: Adaptation of antibody-based detection methods for single-cell analysis to understand cell-to-cell variability in YER187W expression and localization.

• Proximity labeling approaches: Combining YER187W Antibody with proximity labeling techniques (BioID, APEX) to identify interaction partners and map protein neighborhoods in native cellular contexts.

• Antibody engineering platforms: Application of biophysics-informed models to design antibodies with customized specificity profiles, potentially enhancing the selectivity and performance of YER187W-targeting antibodies .

• Active learning integration: Implementation of machine learning strategies to optimize experimental resource utilization, particularly for characterizing antibody-antigen binding properties across multiple conditions .

• Multi-parametric antibody profiling: Integration of multiple antibody-based detection methods with computational analysis to create comprehensive profiles of YER187W expression, modification, and interaction patterns across different cellular conditions.

The combination of biophysics-informed modeling with extensive selection experiments offers a powerful approach for designing proteins with desired physical properties, extending beyond antibodies to broader protein engineering applications .

What methodological advances might address current limitations in antibody-based yeast protein detection?

Several methodological advances show promise for addressing current limitations in antibody-based yeast protein detection:

• Intrabody development: Genetically encoded recombinant antibodies expressed intracellularly can overcome membrane permeability issues and provide temporal and spatial control over protein inhibition or visualization .

• Nanobody adaptation: Single-domain antibody fragments derived from camelid antibodies offer advantages in size, stability, and access to cryptic epitopes that may be inaccessible to conventional antibodies.

• Epitope-specific antibody development: Computational design of antibodies targeting specific protein regions can enhance specificity and enable detection of particular protein states or conformations .

• Multiplexed detection systems: Development of antibody panels with complementary specificities can provide more comprehensive protein characterization and internal validation.

• Standardized validation frameworks: Implementation of systematic validation approaches, such as those employed by YCharOS, can enhance confidence in antibody specificity and performance across applications .

Recent research demonstrates that renewable and recombinant antibodies can serve as valuable tools for controlling protein function, offering perspectives on future research avenues that may be opened by emerging technologies for engineering recombinant antibodies with enhanced utility .